Cyclacel Pharmaceuticals, Inc. (CYCC)

NASDAQ: CYCC · IEX Real-Time Price · USD
0.270
-0.030 (-10.03%)
At close: Dec 1, 2023, 4:00 PM
0.286
+0.017 (6.11%)
After-hours: Dec 1, 2023, 7:42 PM EST
-10.03%
Market Cap 3.41M
Revenue (ttm) 389,000
Net Income (ttm) -24.90M
Shares Out 12.64M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 451,407
Open 0.290
Previous Close 0.300
Day's Range 0.252 - 0.337
52-Week Range 0.253 - 1.170
Beta 1.06
Analysts Buy
Price Target 8.00 (+2,864.06%)
Earnings Date Nov 13, 2023

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leuk... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CYCC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for CYCC stock is "Buy" and the 12-month stock price forecast is $8.0.

Price Target
$8.0
(2,864.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

3 days ago - GlobeNewsWire

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

5 days ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib -

20 days ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

26 days ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

4 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

- Key Catalysts ahead with multiple Value Generating Readouts - - Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib - - Advancing single-agent Efficacy with Differentiated Oral Plogosert...

7 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

7 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

7 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...

9 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update

- On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 -

9 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results

BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

9 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

10 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib –

11 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023

BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma -

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

1 year ago - GlobeNewsWire

Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients Daily dosing of fadraciclib was well tolerated; s...

1 year ago - GlobeNewsWire

Cyclacel Hosting Research & Development Day

-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

- Oral fadraciclib demonstrated good tolerability with continuous dosing;  anticipate entering Phase 2 POC stage in 2H 2022 –

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

1 year ago - GlobeNewsWire

Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H...

1 year ago - Benzinga

Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D.

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

1 year ago - GlobeNewsWire